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Abstract:  Myocardial  infarction  results in loss of cardiac muscle  and deficiency  in cardiac performance.  Likewise,  pe- 
ripheral artery disease can result in critical limb ischemia leading to reduced mobility, non-healing ulcers, gangrene and 
amputation. Both of these common conditions diminish quality of life and enhance risk of mortality. Successful advances 
in treatment have led to more people surviving incidences of myocardial infarction or living with peripheral artery disease. 
However, the current treatments  are inadequate in repairing  ischemic tissue. Over the last 5 years, a vast number of pat- 
ents have been submitted concerning the use of stem cells, which correlates with the exponential growth in stem cell pub- 
lications. Exploiting  stem cell therapy offers a real potential in replacing ischemic tissue with functional cells. In this pa- 
per, we review recent patents concerning  stem cell therapy that have the potential to provide or potentiate novel treatment 
for ischemic cardiovascular  disease. In addition, we evaluate the promise of the inventions by describing some clinical tri- 
als that are currently  taking place, as well as considering  how current  research  on ischemic cardiovascular  disease may 
change the patent landscape in the future. 
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INTRODUCTION 
 
The use of cultured cells in tissue repair dates back to the beginning of the 20
th 
century [1]. The huge potential for stem cells to 
deliver cell-driven repair arises from their distinct properties  that  include  immunological  tolerance  as  an  allo- 
genic  transplant,  potential  to develop  into  multiple  lineages and relative ease of harvesting  and expansion.  These proper- ties  
initiated  a great  determination  to understand  how  stem cells can be fully utilized in a wide range of diseases. The 90’s saw a great 
burst in publications on stem cells which has been growing  exponentially  ever  since  Fig. (1a)  [2]. Research  in stem cells has 
driven the unmistakable confidence, ability and ambition in regenerative medicine, which is reflected in the number of patent 
submissions claiming unique intellectual property within this field. Since 1990 there has been approxi- mately 5500 patents regarding 
stem cells, remarkably half of these have been submitted in the last 5 years Fig. (1b) [2]. We have focused this review on how stem 
cell technology would benefit ischemia cardiovascular  disease of the heart (myocar- dial infarction (MI)) and lower limb 
(peripheral artery disease (PAD)).   We  have  highlighted   how  stem  cell  technologycan be utilized  and document  recent 
submitted  patents  and current clinical trials associated with these diseases. 
 
MYOCARDIAL INFARCTION 
 
The European Society of Cardiology estimated that car- diovascular disease is responsible for 1.9 million deaths each year in the 
EU, which equates to 40% of all deaths within the EU. In the UK, it is projected  that there  are 103,000  MIs each year [3], with 
similar numbers found in most other European countries. The survival rate of people who suffer a heart attack is increasing as a 
result of better knowledge and treatment  of  the  disease.  Subsequently,  more  patients  are now living with their heart in a 
compromised state [3]. In the post-infarcted heart, a large area of the myocardium remains non-functional as a result of ischemia, 
causing remodeling of the non-infarcted region and fibrosis, triggering abnormal filling, pumping and electrical signaling of the 
heart. Current treatment with therapy only treats the symptoms but does not tackle the primary  issue of loss of cardiac tissue. 
Repair of the ischemic heart using a pool of easily sourced human cells is the holy grail of cardiovascular  medicine  and would  
in- crease the long term survival rate and quality of life of peo- ple who have suffered from a myocardial infarction [1]. 
 
PERIPHERAL ARTERY DISEASE 
 
PAD   affects   an  estimated   27  million   people   across 
Northern  America  and  Europe  [4,  5].  PAD  is  caused  by 
 
   
 
 
Fig. (1). Number of publications  and patents submitted  relating  to stem cell corresponding  to their publication  year. Fig. (1a), number of 
publications  regarding  “ stem cell” returned  corresponding  to the publication  year using NCBI biomedical  search site (pubmed.gov  [77]). 
Fig.  (1b);  number  of  patents  submitted  worldwide  over  the  corresponding   years  searched  using  Espacenet  worldwide  patent  search 
(www.epo.org)  [2]. 
 
atherosclerosis in the lower extremities or abdomen, usually presented  clinically as intermittent claudication  [5]. Patients are 
initially faced with worsening burden from chronic pain whilst walking, to non-healing ulcers, gangrene and finally potential limb 
loss [6]. Increased risk of other cardiovascular diseases (CVD) events are high for instance PAD is the third leading cause of 
atherosclerotic cardiovascular morbidity. As 
7-8% of the population  in Europe [4] is predicted  to suffer from PAD, this has a significant  consequence  on the econ- omy  
and  health  care  systems  [6].  Restoring  perfusion  in PAD patients to improve blood flow to the ischemic tissue would  alleviate  
the  pain  and  also  offer  the  best  possible chance of preventing amputation. Stem cells have the ability to promote collateral 
vessel growth, which would achieve the aspired therapeutic angiogenesis [7]. 
 
SOURCES OF STEM CELL 
 
A number  of stem  cell and  progenitor  cell populations have  the potential  to be employed  to aid  cardiac  repair  or relieve 
peripheral ischemia. There are disadvantages and advantages  for each cell type and some such as embryonic stem cells have 
further ethical limitations to overcome. The health status of the donor patient has a great impact on the number  and effectiveness  
of stem cells [8]. We briefly de- scribe some of the sources of stem cells. 
 
Endothelial  Progenitor  Cells (EPCs) have been defined to express CD133+, CD34+ and vascular endothelial growth factor 
receptor-2 [9]. EPCs have been suggested to potentially bolster  neovascularization  by differentiating  into  endothelial cells at the 
site of ischemia. Isolation of EPC cells were found 
to  mostly  contain  a  mononuclear  cell  (CD14
+
/CD34
+
)  sub- 
population, interestingly these cell have the potential to aid angiogenesis  through release of paracrine factors [10]. There is 
controversy in use of EPCs in stem cell research as EPC characterization,  isolation,  and  mechanism  of  action  are far from being 
fully understood and standardized. In addition, elderly, diabetics and patients with cardiovascular  disease all 
 have low EPC numbers [11]; moreover the angiogenic capac- ity of their EPCs is significantly reduced thus limiting the therapeutic 
usefulness. 
CD133+  Cells.  Early  hematopoietic  stem  cells  (HSCs) and EPCs both express the cell surface antigen  CD133 and both 
synergistically  enhance vascularization  of ischemic tissues by differentiating into endothelial cells at the site of ischemia. CD133+ 
cells numbers are severely limited for therapeutic value, very small proportion (approximately  1%) of bone marrow cells (BMCs) 
are CD133+. Furthermore CD133+ cells can’t be expanded ex vivo [12]. 
 
Mesenchymal  Stem Cells (MSCs) are routinely isolated from bone marrow, selected and expanded in culture. MSCs have 
the potential in theory to differentiate into any of the mesodermal linage which includes smooth, skeletal and car- diac muscle.  
However,  the ability of MSCs  to differentiate into cardiomyocytes  is rare in vivo. MSCs may have a posi- tive paracrine effect 
by secreting anti-inflammatory, anti- apoptotic and pro-angiogenic factors [13]. 
 
Resident Stem Cells  A pool of resident cardiac progenitor cells (CPCs) have been identified in the heart that can differ- entiate  
into  new  cardiomyocytes   [14],  endothelial  cells  or smooth muscle cells [12], thus changing the textbook-concept of the 
terminally differentiated heart. CPC population com- prises of cardiosphere-dervived cells (CDCs), cardiomyocyte progenitor cells 
(CMPCs) and c-kit+ cardiac stem cell (CSCs) [15]. CPCs have the potential advantage of fully replacing damaged myocardium. 
However, the disadvantages of using CPCs include low yield, specialist requirement to obtain car- diac biopsy and slow 
amplification [16]. 
 
Vascular Resident Stem Cells. Similar to the heart, all three layers of the vasculature (intima, media and adventitia) contain 
a pool of resident progenitor cell populations which include EPCs, MSCs, CD34+ and Sca-1+ [17, 18] Likewise, these cells 
have the potential to enhance neovascularization. 
 
Bone Marrow  Mononuclear  Cells (BMMSCs) are popular candidates for cell based therapy owing to their rela- 
   
 
 tively  ease and amplitude  of harvesting  under GMP  condi- tions. Moreover, BMMNCs comprise of HSCs, MSCs and EPCs, 
therefore ensure the synergetic advantages of various stem cell populations. BMMNCs have the potential ability to differentiate 
into cardiac or endothelial cell types, providing paracrine signals [16]. 
 
Embryonic Stem Cells (ESCs) are totipotent stem cells harvested  from the inner cell mass of blastocysts  (4-5 days post 
fertilization). ESCs have the immense potential to dif- ferentiate into derivatives of all the three cell types ectoderm, endoderm and 
mesoderm, provide a possible source for car- diomyocytes  or  endothelial  cells.  Importantly,  human  ES cell-derived  
cardiomyocytes  are  able  to  couple  electrically with the host myocardium as well as displaying similar struc- tural and functional 
properties. The major obstacles are the ethical issues related to the use and destruction of human embryos.  Nevertheless,  clinical  
trials  in  the  US  on  hESC have been approved for treating spinal cord injury and macu- lar degeneration [19]. 
 
Induced  Pluripotent  Stem Cells (iPSCs)  may hold the key to bypassing  ethical issues in ESCs [10]. This technol- ogy 
reprograms adult differentiated cells to pluripotency, matching the potential and capability of ESCs. Some of the major limitations of 
iPSC technology include efficacy of generation rates and potential for mutation [20]. 
 
PRE-CLINICAL STEM CELLS THERAPY TO TREAT MYOCARDIAL INFARCTION 
 
In an early study, by Orlic et al. HSCs were injected into the infarct boarder zone in mice subjected to coronary artery 
ligation [21]. Newly formed HSC-derived myocytes were observed that had replaced the infarcted area and importantly vascular 
structures were evident. There is controversy in the field regarding these experiments, debating whether the HSC injection 
actually replaced cardiomyocytes  directly or via an indirect method such as paracrine signaling or stimulating an endogenous 
cardiomyocyte progenitor cell pool [12]. Never- theless, it is clear that cardiac function is enhanced  through HSC injection. 
Indeed some studies have shown that condi- tioned  media from human  MSC can improve  cardiac func- tion post-MI [22]. 
 
More  recent  studies  have  shown  that  human  CPCs  are able to survive and differentiate into cardiac cell types after injection  
into  the  border-zone  minutes  after  infarction  in murine hearts. Most promising,  CPCs had a positive impact left ventricle 
(LV) function, infarct size, vascularization  and fibrosis [23]. 
A more realistic timeline for clinical application whereby administration  of  CPCs  occurred  several  months  post-MI, still 
resulted in positive effects on LV function [24]. Trans- plantation  of  clinical  scale  human  ES-derived  cardiomyo- cytes that had 
been successfully cryopreserved was recently investigated. Administration of human ESC-derived cardio- myocytes were 
effectively engrafted to the myocardium  in a non-human primate model of myocardial infarction [19]. Crucially, these were able 
to provide substantial new cardiac 
   
muscle, that had regular calcium transients and synchronized electrocardiograms,  and vascularization  of the graft from host vessels 
[19]. Scaling up the cryopreservation of hESC-derived cardiomyocytes  promises  a  fast  and  effective  methodology that could be 
widely utilized in medical centers that lack stem cell expertise. Such is the promise of this technology clinical trials have been 
raced through without complete understanding of the exact mechanism [12]. Small trials with a vast range of different conditions  
have taken place, not all of which have been positive. However, taken together with the growing ex- perimental evidence from in 
vivo models stem cell therapy is still a viable method to treat MI [25]. Studies are now investi- gating ways in which the survival of 
the transplanted stem cell population  can  be  enhanced  in  the  myocardium.  Currently, early pre-clinical in vivo models provide 
information on po- tential future patents. Inhibition of the Renin pathway [26] protection  by  enhancement  of  the  pro-angiogenic   
receptor Notch 1 [27], and overexpression  of myocardin,  a transcrip- tion co-activator [28] are all approaches adapting the host 
en- vironment to potentiate the effect of the stem cells. Other tac- tics consider modifying the progenitor cells themselves. Inhi- 
bition of HDAC4, involved in transcription regulation [29] or inositol  hexakisphosphate  kinases  (IP6Ks)  to  enhance  AKT [30] 
are two current trends published this year. 
 
PRE-CLINICAL STEM CELL THERAPY TO TREAT PAD 
 
Over  15  years  ago,  isolation  of  endothelial  progenitor cells (CD34+)  from human peripheral  blood was described to 
differentiate into endothelial cells and incorporate into the vasculature of the experimental ischemic limb [31]. Shortly afterwards, 
Hamano et al. demonstrated that bone marrow injected into the ischemic muscle could induce angiogenesis promoting blood flow 
recovery in rodent ischemic model via elevated bFGF, IL-1f3 levels and possible stem cell incorpo- ration [32]. 
 
Over the preceding years studies have taken place to at- tempt to improve the effectiveness of stem cell therapy in the ischemic  
limb,  these include  ways  to initiate  resident  stem cell populations, modify exogenous stem cells, or change the host  
environment.   MSCs  can  release   cytokines   such  as VEGF and bFGF to promote recovery [33]. Mobilization of resident  
hematopoietic  stem  cell  niche  by  combined  treat- ment of G-CSF and parathyroid hormone (PTH) improved blood flow 
recovery in hindlimb ischemia [34]. A similar beneficial effect of PTH was observed in MI model [35]. Combination of mural and 
endothelial cells derived from ES cells provided an alternative method of enhancing the thera- peutic benefit. Endothelial and 
mural cell differentiated from embryonic cells-positive for VEGFR2 and were incorporated into the host vasculature as 
endothelial cells and mural cells improving vessel integrity thus benefiting recovery of the ischemic hindlimb [36]. Alternatively, 
priming hMSCs to induce VEGF and HGF secretion potentiated stem cell therapeutic effectiveness [37]. 
An  encouraging  development  for  PAD  treatment  is the use  of  CTX0E03  a clinical  grade  human  neural  stem  cell 
line, which  has been  previously  shown  to be beneficial  in pre-clinical stroke models by promoting neurogenesis and 
angiogenesis  [38].  Dose  dependent  improvements  in blood flow recovery was observed in mouse model of PAD (hind limb 
ischemia), suggesting that CTX0E03 may have wider benefits than treatment of stroke [39]. Patents for use of CTX0E03 in treating 
PAD have been submitted and a clini- cal trial is underway both of which will be discussed later. 
Another example of how the host microenvironment  can be altered to enhance the effectiveness of BMC therapy is through co-
treatment with antioxidants to reduce oxidative stress, inflammatory  cell infiltration in the ischemic limb as well as enhancing 
plasma NO bioavailability [40]. 
 
OXIDATIVE STRESS 
 
Oxidative stress is a hallmark of cardiovascular  diseases, strong correlations have been found in MI, PAD, stroke, 
atherosclerosis, LV hypertrophy, intermittent claudication, critical limb ischemia, and insulin resistance [41, 42]. 
Oxidative stress involves the generation of reactive oxy- gen or nitrogen species (ROS/RNS), for example superoxide, 
peroxides,  hydrogen  peroxide  and  peroxynitrite  to  name  a few. High levels of ROS/RNS have long-term detrimental effects  on  
cellular  function  under  pathological  conditions, but are also recognized as pivotal to cellular signaling in physiological pathways 
[43]. ROS/RNS can regulate cellular signaling through oxidative post-translation modification of cysteine residues on key proteins. 
The distinct properties of cysteine residues allow a range of reversible or irreversible oxPTMs, which are largely dependent upon the 
level of ROS/RNS  or  antioxidants.  Thus,  cysteine  residues  act  as sensors detecting ROS/RNS levels providing a mechanistic 
switch to control protein function [44]. There are a number of antioxidant pathways within the cell to balance the cellu- lar and 
microenvironments (redox state) such as superoxide dismutase,  catalase,  glutathione  peroxidase,  peroxiredoxins, and sulfiredoxin 
[44]. 
Of  interest  to  this  review,  oxidative  stress  can  perturb tissue homeostasis by damaging stem and progenitor cells, leading to 
aberrant cell proliferation and anomalous differen- tiation patterns in the affected tissue [45]. 
ROS levels correlate with stem cells (SCs) differentiation capability. High ROS levels are associated with greater differ- entiation 
of SC, whereas low ROS levels are thought to be protective  towards  SC  by  maintaining  them  in  a  quiescent state [46]. 
Comparison of mature endothelial Cells (ECs) with EPCs suggests that EPCs have lower ROS levels as a result of higher antioxidant 
(MnSOD, catalase and glutathione peroxi- dase)  expression.  Low  ROS  levels  are  thought  to  preserve EPCs  undifferentiated  and 
self-renewing  properties  essential for EPCs ability to aid in treatment of disease. Whereas, cyto- kine stimulation (e.g. G-CSF) of 
HSC mobilization into the circulation is mediated via ROS signaling [47]. Redox signal- ing plays an important role in modulating 
SC function, upset- ting of the redox homeostatsis outside a narrow window may be detrimental to SC function [48]. Exploiting 
the fine tuning through  regulation  of  antioxidant  and  ROS  generating  en- zymes may provide a therapeutic advantage to aid stem 
cell therapy. 
 
 
ENHANCING RETENTION OF STEM CELLS 
 
Crucial to successful stem cell therapy is the strategy for cell delivery. Adequate numbers are needed to be supplied to the 
organ and these numbers need to be retained. Delivery approaches to the heart are more complicated than peripheral muscle. 
Intravenous MSC therapy is the easiest and most practical, however a major drawback  are stem cells becom- ing confined in the 
pulmonary circulation [49]. Transendo- cardial injection provides a low invasive method of stem cell delivery. Stem Cells are 
directly delivered to the infarcted region using a catheter guided by fluoroscopic guidance or electroanatomic mapping [50]. Cardiac 
perforation or ar- rhythmias are risk factors that require managing. In contrast, direct intramyocardial  injection allow direct 
visualization  of the infarcted myocardium, and perforation can be controlled [51]. However, this method is highly invasive requiring 
a thoracotomy  or sternotomy.  Intracoronary  infusion  of stem cells using a standard  over-the-wire  balloon  angioplasty  al- lows 
a brief period facilitating stem cell retention in the myocardium while the balloon is inflated to stop blood flow [50]. Although, 
reduced blood flow in the ischemic muscle may prevent effective stem cell delivery; in addition inflation of catheter-balloon may 
cause further ischemia. However, angioplasty  techniques are common procedures for cardiolo- gists, in addition these techniques 
are now used as front line methods in rapid treatment for acute MI upon presentation in emergency  rooms. Therefore,  this 
method of delivery could be dovetailed into current treatment strategies. 
The local microenvironment  is pivotal to the cell reten- tion as this can impact on cell adhesion, migration and stem cell 
survival [12]. Co-administration  or priming  the muscle prior  to stem  cell delivery  could  modify  the microenviron- ment to a 
more favorable status for stem cell function. Alter- natively, genetic manipulation  or pharmacological  treatment of the stem cells 
may also have beneficial effects. BM-MSCs were genetically  modified  to express  the anti-apoptotic  and anti-inflammatory 
enzyme, heme oxygenase-1 (HO-1). Im- proved cardiac function was observed in a swine MI model 3 months after treatment with 
HO-1 transfected-MSCs [52]. 
 
PATENTS AND PUBLICATIONS 
 
Some of the recent patents that have submitted to utilize stem cells for the treatment or that can benefit patients with MI or 
PAD are reviewed  below and further summarized  in Table 1. The expected therapeutic aims of the patents are to improve 
retention of stem cells to the site of ischemia, stabi- lization, efficacy by synergistic mechanism such as paracrine secretion. 
 
STEM CELL- BASED THERAPY 
 
The patent WO2013126590  [53] describes  the use of a cell  population  comprising  of  CD34+  stem  cells  isolated 
 
Table 1. Patents Submitted for Treatment of Myocardial Ischemia or Peripheral Artery Disease by Stem Cell Therapy 
 
Patent Number 
[Reference] 
Title Inventors/Assignees Published 
Date 
Description 
Stem cell 
WO2013126590 
[53] 
Pharmaceutical composition 
comprising CD34+ cells 
Palmer, L., Motlagh, D., Cohen, 
A., Amrani, D.L. 
2013 Treatment of ischemic conditions and 
diseases using a cell population compris- 
ing CD34+ cells isolated from peripheral 
blood of a subject 
US20040258670 
[54] 
Introducing enriched human 
endothelial generating cells and 
mesenchymal stem cells; en- 
hancing vasculogenesis and 
collateralization around blocked 
and/or narrowed vessels 
Mary, L., Stephen, H., Vincent, P. 2004 Administration of endothelial precursor or 
Mesenchymal stem cells enriched for 
CD133+/CD34+ cells to improve vascu- 
larization in the preferred setting of 
ischemic myocardium. 
EP2428563 
[55] 
Vascular/lymphatic endothelial 
cells 
Prosper, F., Verfaillie, C.M., 
Lopez-Aranguren, X., Claver, 
C.C., Luttun, A. 
2012 Method to differentiate cells into more 
than one embryonic lineage 
WO2014022373 
[56] 
Treatment of pulmonary arterial 
hypertension with mesenchy- 
mal stem cells 
Jeffs, R., Petersen, T., Ilagan, 
R.M., Wade, M. 
2014 Method for treating or preventing vascu- 
lopathy administrating pharmaceutical 
composition comprising mesenchymal 
precursor cells 
US20110250182 
[57] 
Angiogenesis using placental 
stem cells 
Abbott, S., Edinger, J.W., Francki, 
A., Hariri, R.J., Jankovic, V., 
Kaplunovsky, A., Labazzo, K., 
Law, E., Padliya, N.D., Paredes, J., 
Wang, J.L./ Anthrogenesis 
Corporation 
2011 Methods of treating individuals having 
diseases or disorders of the circulatory 
system, using placental cells 
   
US20130156726 
[58] 
Endometrial stem cells and 
methods of making and using 
same 
Ichim, T.E., Meng, X., Riordan, 
N.H./ Medistem Laboratories, Inc. 
2013 Pluripotent stem cells and methods for 
making and using pluripotent stem cells 
US20130315875 
[59] 
Amnion derived adherent cells Abbott, S., Edinger, J.W., Francki, 
A., Hariri, R.J., Jankovic, V., 
Kaplunovsky, A., Labazzo, K., 
Law, E., Padliya, N.D., Paredes, J., 
Wang, J.L./ Anthrogenesis 
Corporation 
2013 Isolation of novel angiogenic cells from 
amnion (AMDAC) for the treatment of 
disrupted blood flow in ischemic disease 
such as ischemic limb or myocardium 
Cells are adherent to tissue culture plastic, 
OCT-4-., CD49f+, CD90+ and HLA-G-. 
US8617538 
[60] 
Mesodermal-like cell popula- 
tion for treating ischemia in 
mammals 
Zoldhelyi, P., Willerson, J.T., Liu, 
Q., Chen, Z.Q./ Board Of Regents 
Of The University Of Texas Sys- 
tem 
2013 Compositions containing mesodermal-like 
multipotent mammalian mononuclear 
cells used for treating ischemia. CD34 and 
M-cadherin 
WO2010089605 
[61] 
Treatment of limd ischemia John, S., Erik, M., Paolo, M 
R. Ltd. 
2010 The use of neural stem cells in the 
manufacture of a medicament for the 
treatment of a patient suffering from 
peripheral arterial disease. The invention 
is particularly suited for treating limb 
ischemia or Buerger's disease 
Modification of host environment or stem cells 
US8455435 
[62] 
Combination of granulocyte- 
colony stimulating factor (G- 
CSF) and DPP-IV inhibitors 
like Vildagliptin or Sitagliptin 
Franz, W.M., Theiss, H., Zaruba, 
M.M., Brunner, S./ Ludwig- 
Maximilians-Universitat Munchen 
2013 Uses and methods of parathyroid hormone 
(PTH, and/or parathyroid hormone-related 
peptide (PTHrP), for recruiting stem cells 
into tissue suffering from ischemia 
 
Table (1) contd…. 
 
 
Patent Number 
[reference] 
Title Inventors/Assignees Published 
Date 
Description 
US20130236433 
[64] 
Methods, compositions, cells, 
and kits for treating ischemic 
injury 
Webster, K.A. 2013 Preconditioning of the ischemic tissue with 
hypoxia-regulated human VEGF and 
human IGF-1, prior to stem cell transplan- 
tation 
WO2011011092 
[66] 
Methods and compositions to 
reduce oxidative stress 
Messina, L.M. 2011 Therapeutic applications for compositions 
that reduce the level of oxidative stress on 
cells using stem cells 
WO2011053896 
[68] 
Hypoxia regulated condition- 
ally silenced aav expressing 
angiogenic inducers 
Webster, K.A. 2011 A composition comprising of a condition- 
ally silenced associated viral vector 
(AAV) encoding at least one of a list of 
pro-angiogenic factors, growth factors, 
cytoprotective/cell survival, cellular mi- 
gration factors and anti-inflammatory 
factors, in the presence of a hypoxia re- 
sponse element (HREs) 
US8343485 [69] Compositions and methods of 
vascular injury repair 
Andrew, L.P., 
Robert, A.P. 
2013 A sterile pharmaceutical compositions 
comprising of CD34+ enriched HSC 
containing a CXCR-4+ subpopulation 
stabilized with addition of serum. 
 
from peripheral blood. The invention provides a pharmaceu- tical composition  comprising  of CD34+ cells, a plasma pro- tein   
and   an   isotonic    solution.    Methods    of   obtaining CD34+ cells from a subject are also provided, illustrating all the steps 
from promoting mobilization  of CD34+ cells from bone  marrow  and  collection  of the  mobilized  CD34+ cells from peripheral 
blood (which optionally involves apheresis). In some embodiments, the method further includes an en- riching step in which 
CD34+ cells are separated from CD34- by  employing  specific  antibodies  or  antigen-binding  frag- ments. Pharmaceutical  
compositions  described  in the patent are to be administered in an amount effective to increase development  of blood  vessels  in  
the damaged  tissue  or to repair the tissue in the subject. The pharmaceutical composi- tion comprising the cells is formulated 
for different types of administration,   such  as  parenteral,   subcutaneous,   intrave- nous, intramuscular, intra-arterial, intrathecal, 
or intraperito- neal, via nasal, spray, oral, aerosol, rectal, or vaginal admini- stration. Cells obtained through these methods can also 
 
be administered via a cell delivery matrix. This patent also cov- ers  association  of  the  stem  cell  population  with  a  second 
moiety, such as a therapeutic agent or a diagnostic agent. 
The  invention  US20040258670   [54]  described  in  this patent relates to delivering a therapeutic quantity of CD133+/CD34+ 
enriched human MSCs and/or endothelial generating cells. The patent covers isolation and enrichment of CD133+/CD34+  
endothelial precursor cells or MSC pref- erably  from  umbilical  cord  blood  but also  covers  isolation from peripheral  blood and 
bone marrow.  The preferred  use of  this  invention  is  to  enrich  endothelial  generating  cells prior to administration  and 
expansion in culture. This inven- 
   
tion is designed to treat ischemic myocardium by increasing blood flow to the ischemic region but also covers treatment of 
other ischemic tissue for example ischemic limb. Route of administration  includes  intravenous  injection  or infusion  in close 
proximity to the ischemic tissue to facilitate migration of the cells to the ischemic tissue such as an intracardiac infusion. The 
patent also covers genetic manipulation of the enriched endothelial  generating cells to additionally  express a recombinant 
polypeptide such as VEGF. 
The invention described in the patent EP2428563 [55] relates to methods and compositions for differentiation of Multipotent 
Adult Progenitor Cells (MAPCs) towards the endothelial lineage with arterial, venous and lymphatic endo- thelial characteristics,  
this will be beneficial in vivo with the differentiation  to  vascular  cells  such  as  arterial  or  venous cells. MAPCs are non-
embryonic, non-germ and non- embryonic germ cells that can differentiate into ectodermal, endodermal  and  mesodermal  cells  
types.  They  are positive for telomerase and Oct-3A (Oct-3/4), and isolated from bone marrow,  brain,  muscle,  placenta,  
umbilical  cord  and  cord blood, liver, spinal cord, blood or skin. MAPCs can differen- tiate in vivo where they can form vascular 
cells, such as arte- rial or venous cells. MAPCs are capable of extensive culture without  loss of differentiation  potential  and 
show  efficient, long term, engraftment and differentiation along multiple developmental lineages in vivo without evidence of 
teratoma formation.  MAPCs  cultured  in  the  presence  of  VEGF165 were found to acquire endothelial cell markers, including 
VEGF-R1  and 2, Tie-1, Tie-2, KDR, Flt-1, CD26,  CD105, avp3,  CD34, VE-cadherin and von Willebrand Factor. They also 
had increased expression of markers for arterial (Hey-2, 
 
 
Dll-4, EphrinB2 and EphrinB1) and venous (EphB4) endo- thelium, demonstrating the potential for arterial and venous endothelial 
differentiation of these cells. A subset of the population  of differentiated  cells  expressed  smooth  muscle actin, a marker of 
smooth muscle, showing that MAPCs can differentiate  into both endothelial  cells  and smooth  muscle cells. Either autologous,  
allogeneic  or xenogeneic  cells can be administered to a patient, moreover in undifferentiated, terminally differentiated  or in a 
partially differentiated  form, genetically  altered  or unaltered,  by direct  introduction  to a site  of  interest,  on  or  around  the  
surface  of  an  acceptable matrix, systemically  or in combination  with a pharmaceuti- cally acceptable carrier in order to repair, 
replace or to pro- mote the growth of existing and new blood vessels. 
The patent WO2014022373  [56] describes a pharmaceu- tical formulation of MSCs, which can be isolated from autologous 
and/or heterologous bone marrow and its admini- stration with/without prostacyclin for treating and preventing peripheral arterial 
disease. This method also includes the use of MPC-derived conditioned culture medium or the MSCs- conditioned  culture  
medium  pre-treated  with  prostacyclin. In some embodiments the formulation also contains endothe- lial precursors  cells (EPCs) 
that are transformed  with a nu- cleic acid that increases the expression or biological activity of a protein  selected  from the 
following  group: endothelial nitric  oxide  synthase  (eNOS),  heme  oxygenase  (HMOX1) and prostacyclin synthase (PTGIS). 
The  patent  US20110250182  [57]  provides  methods  of using PDACs (placenta derived adherent cells), to promote 
angiogenesis, and to treat diseases or disorders of the circula- tory system (for example Ischemic Diseases) by improving 
angiogenesis. Disruption of placental tissue using enzymatic digestion or perfusion allows for the isolation of the desired PDACs.  
Administration  of PDACs  can be implanted  alone or in combination with a matrix by injection, infusion and by delivery via 
catheter. PDACs could be incubated or cultured in the presence  of factors that stimulate  stem or progenitor cell differentiation 
according to a cardiogenic, angiogenic, hemangiogenic, or vasculogenic pathway, such as growth factors, chemokines, cytokines, 
cellular products, demethy- lating agents, and other factors which are known to stimulate cell trans-differentiation.  Inventors 
report that the control of the trans-differentiation can be assessed by evaluating the expression of at least one of the following 
markers such as cardiomyosin, skeletal myosin, or GATA4, or by functional parameters  as  the  acquisition  of  a  beating  rhythm  
which can be spontaneous  or otherwise induced, or by the ability of cell engraftment into the cardiac muscle of the patient 
without  inducing  arrhythmias.   The  number  and  type  of cells  collected  from  a mammalian  placenta  can  be  moni- tored,  
for example,  by  measuring  changes  in morphology and cell surface markers using standard cell detection tech- niques such 
as flow cytometry, cell sorting, immunocyto- chemistry, fluorescence activated cell sorting (FACS), magnetic activated cell 
sorting (MACS), by examination of the morphology of cells using light or confocal microscopy, and by measuring  changes in 
gene expression by PCR and gene expression  profiling. Different preparation  of placen- 
   
tal cells, obtained from different subjects, can be stored in a dedicated cell bank for long-term storage. PDACs could be 
genetically engineered to produce recombinant or exogenous cytokines associated with and they can be conditionally im- mortalized  
by transfection  with any suitable vector contain- ing  a  growth-promoting   gene.  Kits  ready  to  use  for  the treatment of MI, 
provide a therapeutic cell composition comprising  of PDACs, which can be prepared in a pharma- ceutically  acceptable  form,  
for  example  by  mixing  with  a carrier, and an applicator. The kits are suitable for the treat- ment of an individual who has a disease 
or disorder of the circulatory system which would allow this therapy to be used in wider medical centers. 
The  invention  US20130156726  [58]  describes  the  use and  isolation  of  pluripotent  stem  cells  to  induce  in  vitro, ex vivo 
and in vivo cell trans-differentiation  into various cell lineages  and  to  produce  conditioned  medium.  The  use  of adult stem cells 
in therapy is limited by their availability, invasiveness of extraction, and in some cases limited prolif- erative capacity, it is also 
necessary to avoid karyotypic ab- normalities  and  potential  oncogenic  transformation  during in vitro culture, this patent 
addresses these critical issues. The invention describes isolated and purification of undifferenti- ated mammalian pluripotent stem 
cells obtained from endo- metrium, endometrial stroma, endometrial membrane or menstrual blood. These cells retain the ability to 
differentiate into one or more different cell types and thus offers the op- portunity to treat a range of conditions. The conditioned 
me- dium can potentially stimulate cell survival and viability, growth, proliferation and differentiation of totipotent, pluri- potent, 
multipotent or differentiated stem cell. It has also the ability to stimulate and to enhance hematopoiesis and/or to inhibit, reduce and 
limit inflammation. The patent also de- scribes  a kit that can be used  to readily  access  pluripotent stem cells, which would 
benefit medical centers without spe- cialist stem cell isolation expertise and equipment. 
The patent US20130315875 [59] provides novel angio- genic cells isolated from amnion, called “amnion derived adherent  cells” 
(AMDACs).  Amnion  derived  adherent cells are  extracted  from  amnion  tissue  by  enzymatic  digestion using one or more 
tissue-digesting enzymes. The number and type of cells collected from amnion can be monitored, for example, by measuring 
changes in morphology and cell sur- face markers using standard cell detection techniques such as immunolocalization, flow 
cytometry, cell sorting, immuno- cytochemistry, fluorescence activated cell sorting (FACS), magnetic activated  cell sorting 
(MACS), by examination  of the morphology  of cells using light or confocal microscopy, and by measuring changes in gene 
expression using PCR and gene expression profiling. These techniques can also be used to identify cells that are positive for one or 
more particular markers.  The patent covers: i) differentiation  of AMDACs, to exhibit at least one characteristic  of an 
endothelial  cell, a myogenic cell, or a pericytic cell; ii) genetic modification of AMDACs, to additionally produce a nucleic acid 
or polypep- tide of interest directly or to produce a differentiated cell (osteogenic  cell, myocytic cell, pericytic cell, or angiogenic 
cell) that produces a nucleic acid or polypeptide  of interest;iii)  a  range  of  compositions  comprising  AMDACs,  which can be 
used in the clinical practice, for instance in pharma- ceutical compositions matrices and scaffolds, and media conditioned  by  amnion  
derived  adherent  cells;  iv)  Condi- tional immortalization  of AMDACs by transfection with any suitable  vector  containing  a  
growth-promoting   gene.  The patent suggests that the benefits from these cells can be used in a number of conditions  including  
ischemic disease to in- duce angiogenesis and differentiation into cardiac or endo- thelial cells. 
 
The patent US20110104124  [60] reports various compo- sitions containing an effective amount of mesodermal-like 
multipotent mammalian mononuclear cells that express both CD34 and M-cadherin cell surface markers. These composi- tions can 
be used in different embodiments  such as prevent- ing, treating or reducing the severity of tissue ischemia or an ischemia 
associated disorder. The method comprises of iso- lation of cells from autologous/heterologous bone marrow displaying  a positive  
expression  for CD34  and  M-cadherin (both 95% of positive surface expression). A minor fraction (10%) of this population can 
also express Pax3 or Pax7. Subsequent  administering  directly to an ischemic tissue siteor an adjacent site, wherein  the dose 
comprises  of 10
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cells bearing both CD34 and M-cadherin  cell surface mark- ers. The employment of this cell population may include the in vivo 
repopulation  with new myocytes and vascularization of the ischemic site. By administrating  the said cell popula- tion,  
functional  new  blood  vessels  formation  can  be  im- proved, and consequently  one or more ischemia  symptoms. In addition, 
the method can comprise the additional admini- stration of angiogenic cytokines to the ischemic or adjacent ischemic  tissue,  
specifically  the  myocardium  or  ischemic limb, to provide synergetic benefit. 
 
This patent additionally utilizes the invention as a diag- nostic marker detecting the level and/or distribution of CD34+/M-
cadherin+ mesodermal-like precursor cells in a mammalian tissue sample. This enables indication of self- repairing ability. 
Alternatively, it can be used to measure success of stem cell transplant. 
 
The  patent  application  WO2010089605   [61]  describes the use of neural stem cells for the treatment of patients suf- fering  
from  peripheral  arterial  disease.  Neural  stem  cells offer an alternative to bone marrow derived stem cells pro- viding a scalable, 
safe and potent allogenic treatment. Neural stem  cells  are  derived  from  ventricular  and  hippocampal regions of fetal and 
adult brain or derived from ESCs which have undergo differentiation to neural stem cells. 
 
The invention US8455435 [62] described in this patent relates to uses and methods of parathyroid  hormone (PTH), and 
parathyroid hormone-related peptide (PTHrP), for re- cruiting stem cells into tissue suffering from ischemia. The patent also covers 
the use of a combination of G-CSF and a dipeptidyl  peptidase  IV (DPP  IV)  inhibitor/antagonist.  The DPP IV 
antagonist/inhibitor  can be used in combination with G-CSF or a G-CSF fragment. Additionally the patent relates to  a  
pharmaceutical  composition  comprising  of  PTH,  and PTHrP   and   G-CSF,   with   and   without   DPP   IV   
inhibitor/antagonist. 
As discussed previously the influence of parathyroid hormone on the HSC niche in the bone marrow strengthens survival and 
self-renewal of hematopoietic stem cells. It is known that PTH has cardiovascular functions such as vaso- dilatation, increased 
 
myocardial blood flow, hypotensive effects, myocardial hypertrophy, positive chronotropic and contractility effects. PTH has the 
ability to work with G-CSF in mobilizing circulating progenitor cell numbers and tissue perfusion [34]. Whereas, inhibition of 
DPP-IV significantly improved  cardiac function after MI in a mouse model [63], in correlation  with increased  mobilization  and 
a higher rate of endothelial  cell proliferation.  This treatment is useful for the recruiting of stem cells from the bone marrow into 
the periphery and, further, is useful for the prevention and treat- ment of ischemia. 
The  invention  US20130236433   [64]  described  in  this patent  is based  on the discovery  that stem  cells,  when  in- jected 
into ischemic tissue of mammals, can be protected by preconditioning  of  the  ischemic  tissue  with  hypoxia- regulated human 
Vascular endothelial growth factor (VEGF) and human Insulin Growth Factor-1 (IGF-1) [65]. In the pat- ent compositions,  cells, 
kits and methods are reported. They include the use of hypoxia-regulated, inflammation-responsive conditionally-silenced nucleic 
acids to promote stem cell survival and vascularization in ischemic disease. It was hy- pothesized that tissue engineering with 
hypoxia-regulated growth and survival factors may reduce toxicity, before stem cell injection,  thus promoting  cell survival and 
the efficacy of the therapy. By using such combination of gene and stem cell therapy, it has been proven to improve both cell 
survival and tissue reperfusion. The invention also describes a typical method   of  treating   tissue  already   injured   or  at  risk  
of ischemic injury in a subject. For instance, the administration to the patient of a therapeutically effective amount of a com- 
position which includes at least one nucleic acid encoding at least one cell survival factor for protecting stem and progeni- tor 
cells from ischemia, and/or alternatively  at least one nu- cleic acid operably  linked  to a hypoxia-regulated  promoter and  
subsequently   administration   to  the  subject  prior  to injection stem and/or progenitor cells. 
The invention WO2011011092 [66] is based on the un- derstanding that oxidative stress is a critical factor regulating stem cell 
function. A physiological balance of the redox state in a cell or a tissue can be achieved by administering a com- position or a 
combination of agents resulting in reversal or reduction of oxidative cell or tissue injury. These include the administration  of one 
or more activators of an anti-oxidative pathway, co-factors, anti-oxidants or free radical scavengers; for  example  L-Arginine,  N-
acetyl-cysteine,  and/or  L- Cysteine,  BH4 (tetrahydrobiopterin)  prior to stem cell ther- apy. 
 
The patent, US20130131152 [67], discusses a method relating  to  the  treatment  of  hypoxia  and  associated  conditions, 
especially directional angiogenesis for therapeutic ad- vantage.  The  method  uses  a conditionally  silenced  adeno-
   
associated vector (AAV) expression system which expresses the desired factor. The method uses a combination of silenc- ers 
such as NRSE and TOAD/FROG  to regulate growth fac- tor  expression  in hypoxia  and  ischemic  affected  tissues  to give a 
more rapid and efficient revascularization and tissue salvage before, during or post injury. This invention  can be used to replace 
the preclinical and gene therapy models fo- cused  on  angiogenesis  which  are  primitive  in  comparison due  to  the  inadequate  
delivery  vehicles  and  constitutively active gene expression that provides non-directional vessel growth. 
The AAV gene expression  is regulated  by the promoter, for example phosphoglycerate kinase (PGK) promoter, in conjunction 
with a combined cassette of hypoxia response element (HRE) along with the combination of silencer ele- ments, which are activated 
by ischemic conditions. The ad- ministration of pro-angiogenic growth factor genes such as; endothelial growth factor, fibroblast 
growth factor (FGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), 
transforming growth factor (TGF), hepatocyte growth factor (HGF), pro- liferin, angitropin, angiopoietin, vascular endothelial growth 
factor (VEGF),  transforming  growth factor beta (TGF-beta) or erythropoietin  (EPO) is a possibility. Further examples of factors 
are c-kit ligand/ stem cell factor, insulin, insulin like growth factor-l (IGF-l), nerve growth factor (NGF), bone morphogenetic   
protein  (BMP),  leukemia  inhibitory  factor (LIF),  brain  derived  neurotrophic  factor  (BDNF),  interleu kins such as but not 
limited to interleukin 3 (IL-3), interleu- kin 6 (IL-6), interleukin 7 (IL-7), and interleukin l3 (IL-l3), stromal derived factor (SDF), 
stem cell factor (SCF), granu- locyte colony stimulating factor (G-CSF), and matrix metal- loproteinase (MMP) inhibitors. 
The conditionally silenced vectors may be used to treat hypoxia associated  condition  such as MI in order to reduce the 
severity of cell/tissue damage during the post ischemic period. 
The methods outline ways to isolate subpopulations in- cluding  but  not  exclusively   adherence   to  plastic  culture dishes 
followed by culture in a selective medium, separation via specific cell markers whether it be due to their expression or  lack  of  
expression,   markers  such  as:  CD133,  CD45, CD34, CD31, Sca-1, c-kit, Thy1, and CD105. The stem cells used in this 
invention can be autologous, allogeneic or xeno- genic. The choice of which depends  on the urgency  of the need for treatment. 
The patent, WO2011053896 [68], outlines methods for treating hypoxia and the conditions associated with it by directional 
angiogenesis/arteriogenesis using conditionally silenced vectors such as adeno-associated virus (AAV) or lentiviral vector, which 
express the required factor for direc- tional  angiogenic  manipulation.  The  system  will  transport the desired genes to target cells 
such as skeletal and cardiac myocytes,  endothelial  cells, smooth  muscle  cells,  pericytes and stem cells. Different stem cells can 
be used such as mus- cle, cardiac, mesenchymal, hematopoietic or endothelial pro- genitor  stem  cells.  The  patent  describes  
the  purification,ex vivo culture, and transfection/infection  with conditionally silenced vectors. 
This invention  is potentially  important  for the treatment of  ischemic   diseases   and  conditions,   where  new  vessel growth 
is vital for the repair and recovery of affected cells, tissues and microenvironments. The treatment relies upon hypoxic conditions to 
regulate the AAV vector through a silencer element, which includes but is not limited to NRSE and  TOAD/FROG  in  a 
heterogeneous  combination,  which are activated in ischemic conditions while inhibited during aerobic conditions. The vector also 
depends upon promoters such as phosphoglycerate kinase (PGK) to regulate pro- angiogenic gene expression alongside hypoxia 
response ele- ments  (HREs),  inflammatory  response  elements  (IREs)  or shear-stress  activated  elements  (SSAEs).  The 
treatment  can be used in concert with a specific drug regime such as vaso- dilators (adenosine, nitric oxide donors such as 
prostagland- ins or antioxidants), to have additional benefits. 
Current therapeutic methods to induce angiogenesis have flaws in their methods; for example, inadequate delivery vehicles that 
extinguished gene expression too early and the delivery  is unregulated  so genes  do not provide  the direc- tional cues needed for 
the correct new vessel growth. This invention could be the answer to deliver a more efficient and robust therapeutic cue to regulate 
angiogenesis. 
 
METHODS AND DIAGNOSTIC 
 
The patent US8343485 [69, 70] provides to a sterile pharmaceutical formulation composed of an enriched CD34+ population 
that contains a subpopulation of CD34+/CXCR-4 cells holding a CXCR-4-mediated chemotactic activity, the methods of 
preparation and its use for the treatment of vas- cular-injury repair, including MI. Moreover, the pharmaceu- tical composition 
contains a stabilizing amount of serum that is characterized as having the said properties for at least 24 hours after that acquisition 
of the chemotactic hematopoietic stem cell product, when tested in vitro after passage through a catheter. 
The chemotactic hematopoietic stem cell factor is prepared by isolating  and  purifying  CD34+  hematopoietic  stem  cells from a 
population of mononuclear  cells isolated from autolo- gous bone marrow and peripheral blood after treatment with a hematopoietic  
stem  cell  mobilizing  agent  (such  as  G-CSF, GM-CSF or a pharmaceutical acceptable analog or derivate). 
The chemotactic hematopoietic stem cell factor contains varying proportions of pure CD34+ cells. The sterile composi- tion 
patented is formulated for parentheral administration in coronary blood vessel, in myocardium, artery, vein or muscle and it can 
contain one of the compatible active agent (hema- topoietic stem cell mobilizing agent), such as angiotensin- converting enzyme 
inhibitor, beta-blocker, a diuretic, anti- arrhythmic agent, anti-anginal agent, anticoagulant, vasoactive agent, fibrinolytic agent, or 
hypercholesteromic agent. 
The sterility of the chemotactic hematopoietic  cell prod- uct is confirmed by a multi-step procedure patented in this protocol. 
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CURRENT & FUTURE DEVELOPMENTS 
 
Reviewing clinical trials offers an informative method to establish the potential, validity, progress and success of claims put 
forward in patents involving medical innovations. Unlike documentation  available for patents it is relatively difficult to accurately  
establish  the exact  number  of worldwide  clinical trials currently taking place in any particular field. There are different publically 
available open databases on clinical trials where information can be sourced; however the data does not always  match  between  
databases.  Nevertheless,  these  data- bases provide  a good  reflection  of the current  trends  in the usage of this technology. The 
United States National Institute of Health Clinical Trial database (ClinicalTrials.gov  [71]) cur- rently provide >1765 open records of 
worldwide trials involv- ing stem cells. Within that group, 53 trials are currently re- cruiting patients for stem cells trials involving 
MI, whereas 27 stated  PAD or critical  limb ischemia  as the target condition 
Table 2. Within the UK there are currently 41 clinical trials ongoing  involving  stem  cells,  cardiovascular  is  the  second most 
common target disease with oncology leading the way (Sourced from Cell Therapy Catapult UK Clinical Trial Data- base [72]). 
Five of the current trials involving  stem cells in- clude MI while one is investigating PAD. 
 
Clinical trial SRCTN65630838,  is a prospective, double- blind randomized trial that will enrich bone marrow derived cells 
using CD133+ selection and test this in patients under- going coronary surgery. This clinical trial appears to be us- ing the 
invention described in patent US20040258670. Autologous  CD133+  stem  cells  will  be  transplanted  into scarred  areas  to  
induce  angiogenesis  and  neomyogenesis. The clinical  endpoint will assess  left ventricular  thickening by MRI, 6 months after 
injection. Secondary outcome meas- urements include left ventricular function, scarring, troponin I levels and quality of life 
scores. 
 
Table 2. Ongoing Clinical Trials for Treatment of Myocardial Infarction and Peripheral Artery Disease. 
 
NCT Number Title Sponsor/Collaborators 
Phase 
Primary/ Secondary Outcome Measures 
NCT00350766 Cell therapy in myocardial infarction Ministry of health, Brazil 
Phase 3 
Global left ventricular ejection fraction change. death. 
Acute myocardial infarction, stroke and hospital 
admission due to cardiovascular cause 
NCT00725738 Intracoronary autologous stem cell trans- 
plantation in ST elevation myocardial 
infarction: Tracia study 
National Heart Institute, 
Mexico|National Center of 
Blood Transfusion Mexico. 
Phase 2/3 
Evaluate the mean LVEF increase by magnetic resonance 
imaging (MRI) at 6 months of follow up between the stem 
cell group and the control group 
NCT01625949 Stem cell therapy in patients with myocar- 
dial infarction and persistent total occlusion 
of infarct related artery 
All India institute of medical 
sciences, New Delhi 
Left ventricular function 
NCT00275977 Treatment of myocardial infarction with 
bone marrow derived stem cells 
Odense University Hospital 
Phase 1 
Safety 
Change in left ventricular funtion at 4 months followup 
using contrast enhanced echocardiography 
NCT01652209 Relief(A randomized, open labeled, multi- 
center trial for safety and efficacy of intra- 
coronary adult human mesenchymal stem 
cells acute myocardial in Farction) 
Pharmicell Co., Ltd. 
Phase 3 
Left ventrical function by MRI 
NCT01536106 Rapid delivery of autologous bone marrow 
derived stem cells in acute myocardial 
infarction patients. 
Totipotent RX cell therapy Pvt. 
Ltd.|TotipotentRX Corpo- 
ration 
Phase 1/Phase 2 
Number of adverse events as a measure of safety. Changes 
in the global left ventricular ejection fraction(LVEF), LV 
volumes-end systolic volume (ESV) and end diastolic vol- 
ume (EDV), infarct size, myocardial mass, myocardial 
viability and regional wall motion abnormalities. Major 
adverse cardiac events (MACE)/Quality of life 
NCT00501917 MAGIC cell-5-combicytokine trial Seoul National University 
Hospital 
Phase 2/Phase 3 
Change of left ventricular ejection fraction measured by 
cardiac MRI 
Wall motion score index exercise capacity BNP 
NCT00437710 Safety and efficacy of bone marrow cell 
transplantation in humans myocardial 
infarction 
Azienda UnitÌÊ Sanitaria 
Locale di Piacenza 
Phase 1/Phase 2 
Mortality and morbidity. left ventricular function and re- 
modeling, baroreflex sensitivity, stress induced myocardial 
ischemia 
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NCT Number Title Sponsor/Collaborators 
Phase 
Primary/ Secondary Outcome Measures 
NCT00650143 Sitagliptin plus granulocyte-colony stimu- 
lating factor in acute myocardial infarction 
Ludwig-Maximilians - Uni- 
versity of Munich|Heinz 
nixdorf-foundation 
Phase 2/Phase 3 
Change of global myocardial function from baseline to 6 
months of follow-up 
Segmental myocardial thickness and volumes in MR/ extent 
of non-viable myocardium will be monitored from baseline 
up to 6 months measured by MRI delayed enhancement 
NCT00529932 A trial using CD133 enriched bone marrow 
cells following primary angioplasty for 
acute myocardial infarction 
Onze Lieve Vrouw Hospi- 
tal|King's College London 
Comparison of changes in myocardial thickening in non- 
viable akinetic / hypokinetic LV wall segments as deter- 
mined by cardiac magnetic resonance imaging (cMRI) in 
treated and control groups 
NCT01781390 Safety study of allogeneic mesenchymal 
precursor cell infusion in myocardial in- 
farction 
Angioblast Sys- 
tems|Mesoblast, 
Inc.|Mesoblast, Ltd.|Teva 
Pharmaceuticals USA 
Phase 2 
Frequency of the total major adverse cardiac and cere- 
brovascular events (MACCE) 
NCT01974128 Study to assess the safety and cardiovascu- 
lar effects of autologous adipose-derived 
stromal cells implantation in patients during 
the acute recovery phase of st-elevation 
myocardial infarction 
Ageless Regenerative Institu- 
te/Instituto de Medicina Rege- 
nerativa, S.A. de C.V. 
Phase 1/Phase 2 
Cardiac improvement 
primary safety objective 
NCT01394432 Estimation study for endocardial mesen- 
chymal stem cells implantation in patients 
after acute myocardial infarction 
Meshalkin research institute of 
pathology of circulation 
Phase 3 
Reduction in left ventricle systolic volume on 15% mesured 
by MRI/All-cause death|number of patients with throm- 
boembolic events|number of heart failure hospitaliza- 
tions/Distance during 6-minute walking test 
NCT01969890 Stem cells mobilization in acute myocardial 
infarction outcome trial 
Heart care foundation/A. 
manzoni hospital/centro 
cardiologico monzino 
Phase 3 
The composite endpoint of: - All cause death or, - recurrence 
of myocardial infarction (MI) or, - hospitalization due to 
heart failure./All cause death and cardiovascular events 
NCT00936819 The enhanced angiogenic cell therapy - 
acute myocardial infarction trial 
Ottawa hospital research 
institute/Canadian institutes of 
health research (CIHR) 
Phase 2 
Assessment of global LVEF, Assessment of: cardiac wall 
motion and volumes, time to clinical worsening 
(TTCW)/Safety measurements 
NCT01454323 Intracoronary infusion of bone marrow 
mononuclear cells in patients with previous 
myocardial infarction 
Fundaciì n PÌYblica Andaluza 
Progresoy Salud 
Phase 2 
Change from baseline in left ventricular ejection fraction 
(LVEF), major adverse cardiac events (MACE), functional 
grade of the new york heart association (NYHA) 
NCT00711542 Effects of intracoronary progenitor cell 
therapy on coronary flow reserve after 
acute MI 
Johann wolfgang goethe 
University Hospi- 
tals/University of Leipzig 
Phase 1/Phase 2 
Improvement of coronary flow reserve in the infarct vessel, 
Improvement of relative coronary flow reserve, Improve- 
ment of global and regional left ventricular ejection fraction 
Major adverse cardiac events (death, MI, rehospitalization 
for heart failure, revascularization). 
NCT01753440 Allogeneic stem cells implantation com- 
bined with coronary bypass grafting in 
patients with ischemic cardiomyopathy 
AHEPA University Hospital 
Phase 2/Phase 3 
Left ventricular ejection fraction. Myocardial segmental 
perfusion 
All-cause mortality and all-cause morbidity. 
Major adverse cardiac and cerebrovascular events 
NCT01758406 Transplantation of autologous cardiac stem 
cells in ischemic heart failure 
Royan Institute 
Phase 2 
Death, arrhythmia, hospitalization, ejection fraction. Pro 
BNP changes. NYHA functional class 
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NCT Number Title Sponsor/Collaborators 
Phase 
Primary/ Secondary Outcome Measures 
NCT01615250 Implantation of peripheral stem cells in 
patient with ischemic cardiomyopathy 
Odessa national medical 
University 
Phase 1 
Change in global left ventricular ejection fraction and re- 
gional wall motion score index. Incidence of the major 
adverse cardiac events 
NCT01337011 Intra-coronary versus intramyocardial 
application of enriched CD133pos autolo- 
gous bone marrow derived stem cells 
Asklepios prore- 
search/Miltenyi Biotec GmbH 
Phase 1/Phase 2 
Change in left ventricular global ejection fraction measured 
via echocardiography improvement of 6min walk. 
Improvement of peak oxygen consumption. Improvement 
of LV function as measured by cardiac MRI 
NCT01693042 Compare the effects of single versus re- 
peated intracoronary application of autolo- 
gous bone marrow-derived mononuclear 
cells on mortality in patients with chronic 
post-infarction heart failure 
Johann wolfgang goethe 
University Hospitals 
Phase 2/Phase 3 
Mortality at 2 years after inclusion into the study. 
Morbidity at 2 and 5 years after inclusion into the study 
NCT01467232 Impact-CABG Trial: Implantation of 
Autologous CD133+ stem cells in patients 
undergoing coronary artery bypass grafting 
University Health Network, 
Toronto|Miltenyi Biotec, Inc. 
Phase 2 
Freedom from major adverse cardiac event. 
freedom from major arrhythmia. 
Regional myocardial perfusion and function assessed by 
magnetic resonance scans. 
Global ventricular function assessed by echocardiographic 
measures of ejection fraction. 
NCT00418418 Combined CABG and stem-cell transplan- 
tation for heart failure 
Helsinki University 
Phase 2 
Ejection fraction and cardiac function of the heart measured 
with MRI or PET ischemia area 
NCT01946048 Umbilical cord derived mesenchymal stem 
cells therapy in ischemic cardiomyopathy 
Hebei Medical University 
Phase 1 
The examination of heart function. 
all-cause mortality and morbidity 
NCT01913886 Mesenchymal stem cells to treat ischemic 
cardiomyopathy 
PontifÌcia Universidade CatÌ- 
lica do ParanÌÁ/Danielle 
Malheiros.Santa Casa de 
MisericÌ_rdia de Curitiba, 
Brazil/FundaÌ¤Ì£o AraucÌÁria, 
Brazil 
Phase 1/Phase 2 
Change from baseline in left ventricular ejection fraction 
(LVEF) measured by echocardiogram. 
Change in quality of life. Changes in exercise capacity 
Changes in plasma inflammatory markers 
NCT01720888 Intracoronary autologous mesenchymal 
stem cells implantation in patients with 
ischemic dilated cardiomyopathy 
National University of Malay- 
sia/Cytopeutics Pte. Ltd. 
Phase 2 
Change in LV volumn, functional status LV ejection fraction 
as measured by echocardiogram and MRI after implantation 
NCT01670981 An efficacy, safety and tolerability study of 
ixmyelocel-t administered via transendo- 
cardial catheter-based injections to subjects 
with heart failure due to ischemic dilated 
cardiomyopathy (IDCM) 
Aastrom biosciences 
Phase 2 
Average number of clinical events over 12 months post- 
treatment 
Change from baseline to 12 months post-treatment in 6- 
minute walk test, left ventricular function as evaluated by 
echocardiography, in quality of life 
NCT02057900 Transplantation of human embryonic stem 
cell-derived progenitors in severe heart 
failure 
Assistance Publique - 
HÌ«pitaux de Paris 
Phase 1 
number and nature of adverse events 
Feasibility of patch's generation and its efficacy on cardiac 
functions 
NCT01098591 Meta-analysis of cell-based cardiac studies: 
Accrue 
Medical University of Vienna/ 
and across Europe 
Freedom from occurrence of major adverse cardiac and 
cerebrovascular events (MACCE), including all-cause death, 
re-infarction, revascularization and stroke 
Hard clinical end point 
Changes in end-diastolic volume, end-systolic volume and 
ejection fraction 
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NCT Number Title Sponsor/Collaborators 
Phase 
Primary/ Secondary Outcome Measures 
NCT02059512 Autologous bone marrow mononuclear 
cells in the combined treatment of coronary 
heart disease 
St. Petersburg State Pavlov 
Medical University 
Phase 3 
All-cause mortality associated with the progression of basic 
disease. 
Quality of life 
NCT01905475 CXCR4 Antagonism for cell mobilisation 
and healing in acute myocardial infarction 
(CATCH-AMI) 
Polyphor Ltd. 
Phase 2 
Change in LVEF and additional measures of cardiovascular 
function as determined by MRI 
Mobilization of stem and progenitor cells 
Pharmacokinetic outcome 
Safety of POL6326 by intravenous infusion 
NCT01033617 Impact-CABG Trial: Implantation of 
Autologous CD133+ stem cells in patients 
Undergoing CABG 
Centre hospitalier de l'Univer- 
sitÌ© de MontrÌ©al 
(CHUM)/Miltenyi Biotec, 
Inc./ Centre de Recherche du 
Centre Hospitalier de l'Univer- 
sitÌ© de Mon- 
trÌ©al/Maisonneuve- 
Rosemont Hospital 
Phase 2 
Freedom from major adverse cardiac event: cardiac death, 
myocardial infarct, repeat coronary bypass grafting or percu- 
taneous intervention of bypassed artery or major arrhythmia 
Regional myocardial perfusion and function assessed by 
magnetic resonance scans. 
Device performance end point: Feasibility to produce from 
100ml of bone marrow aspiration a final cell product that 
contains a target CD133+ cells higher than 0.5 
million with a purity superior to 30% and a recovery supe- 
rior to 10%. 
NCT01458405 Allogeneic heart stem cells to achieve 
myocardial regeneration 
Capricor Inc./National Insti- 
tutes of Health (NIH)/National 
Heart, Lung, and Blood Insti- 
tute (NHLBI) 
Phase 1/Phase 2 
Infarct size assessed by MRI 
NCT00394498 Stem cell mobilization by G-CSF post 
myocardial infarction to promote myocyte 
repair 
University of Ot- 
tawa/Canadian Institutes of 
Health Research (CIHR) 
Phase 2/Phase 3 
6 month Left ventricular ejection fraction, myocardial FDG- 
PET uptake, myocardial ammonia-PET perfusion, 
6 week/month left ventricular diastolic and systolic volume 
NCT01234181 Clinical study of hypoxia-stressed bone 
marrow mononuclear cell transplantation to 
treat heart diseases 
Second affiliated hospital, 
School of Medicine, Zhejiang 
University 
Heart function 
NCT01569178 BAMI. The effect of intracoronary reinfu- 
sion of bone marrow-derived mononuclear 
cells(BM-MNC) on all-cause mortality in 
acute myocardial infarction 
Barts & The London NHS 
Trust 
Phase 3 
Time from randomization to all-cause death/Time from 
randomization to cardiac death 
time from randomization to cardiovascular re-hospitalisation 
incidence and severity of adverse events 
bleeding by BARC definition 
NCT01813045 Angiogenesis and fibrosis in myocardial 
infarction 
University of Edinburgh The primary outcome is heart function determined by ejec- 
tion fraction (in %) 6 months following a heart attack. 
Extent of fibrosis (% late gadolinium enhancement) & blood 
flow 6 months post-MI, and the correlation with integrin 
expression at 9 weeks (fluciclatide distribution through the 
myocardium viewed on CTPET images) 
NCT01127113 Inflammatory cell trafficking after myocar- 
dial infarction 
University of Edin- 
burgh/British Heart Founda- 
tion 
Change in cardiac MRI signal intensity from baseline after 
administration of labelled vs. unlabelled mononuclear cells 
Correlation of myocardial MRI signal intensity change from 
baseline with markers of systemic inflammation. 
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Phase 
Primary/ Secondary Outcome Measures 
NCT02052427 Safety & efficacy of adipose-derived regen- 
erative cells in the treatment of chronic 
myocardial ischemia (ATHENA II) 
Cytori therapeutics 
Phase 2 
Primary efficacy - Change in minnesota living with heart 
failure questionnaire 
Secondary efficacy - change in mVO2. Change in 
LVESV/LVEDV, Ejection Fraction, perfusion defect, heart 
failure symptoms, angina, and quality of life. 
NCT00950274 Intramyocardial transplantation of bone 
marrow stem cells in addition to coronary 
artery bypass graft (CABG) surgery 
Miltenyi Biotec 
GmbH/German Federal Minis- 
try of Education and Research 
Phase 3 
Left ventricular ejection fraction at rest, measured by MRI 
Change in LVEF as assessed by MRI and echocardiography 
Regional contractility in the AOI / Change in LV dimen- 
sions 
Physical exercise capacity determined by 6 minute walk test 
NCT01267331 Cell therapy in patients with chronic 
ischemic heart disease undergoing cardiac 
surgery 
Chinese PLA general hospital 
Phase 1/Phase 2 
Major adverse cardiac events 
Left ventricular function 
NCT00984178 Trial of hematopoietic stem cells in acute 
myocardial infarction 
Tecam Group|Hospital Gen- 
eral Universitario Gregorio 
Maraìon 
Phase 2 
The change in left ventricular ejection fraction and left 
ventricular end-systolic volume relative to baseline meas- 
ured by magnetic resonance 
The change in left ventricle end-diastolic volume, segment 
contractility, wall thickness and intravascular ultrasound 
reendothelization relative to baseline measured by magnetic 
resonance and other imaging techniques 
To determine the safety of the study procedures 
NCT01770613 A study of allogeneic mesenchymal bone 
marrow cells in subjects with st segment 
elevation myocardial infarction (STEMI) 
Stemedica cell technologies, 
Inc./Mercy gilbert medical 
center at AZ/Chandler regional 
medical center at chandler 
AZ/University of California, 
San Diego 
Phase 2 
The safety and tolerability of a MBMC intravenous admini- 
stration during the twelve month study period as determined 
by major adverse events MACE endpoint.| 
LV end diastolic and systolic volume 
Infarct size measured by MRI, with and without contrast 
(only for patients eligible for MRI 
Global left ventricular ejection fraction (measured by 
echocardiography 
Peripheral artery disease 
NCT01456819 Intramuscular mononuclear cells and mes- 
enchymal stem cells transplantation to treat 
chronic critical limb ischemia 
National University of Malay- 
sia/Cytopeutics Pte. Ltd. 
Phase 2 
Change in angiogenesis 
Change in blood supply 
Change in ulcer size 
Visual Analog Score 
Exercise Treadmill Test 
NCT02099500 Autologous adipose-derived stromal cell 
delivered via intramuscular injections for 
the treatment of critical limb ischemia 
Ageless regenerative institute 
Phase 1/Phase 2 
Improvement from baseline in perfusion as measured by 
ankle-brachial index and collateral artery number/ 
Number of adverse events reported 
Improvement from baseline in improvement or resolution of 
ulcer or gangrene 
Limb Salvage 
NCT01867190 Study to assess efficacy and safety of bone 
marrow derived stem cells in patients with 
critical limb ischemia 
Lifecells, LLC. 
Phase 1/Phase 2 
To assess the efficacy and safety of intra-arterial infusion 
and intramuscular injection of ASCT01 on the combined 
primary endpoint of major amputation (above the ankle) or 
persisting critical limb ischemia (no clinical or perfusion 
improvement) 
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NCT02145897 To evaluate the safety and efficacy of IM 
and IV administration of autologous 
ADMSCs for treatment of CLI 
Kasiak Research Pvt. Ltd. 
Phase 1/Phase 2 
To assess the safety 
To assess the efficacy 
NCT01408381 Intra-arterial infusion of autologous bone 
marrow mononuclear cells in non-diabetic 
patients with critical limb ischemia 
Fundaciìn PÌ\1blica Andaluza 
Progresoy Salud/Iniciativa 
Andaluza en terapias Avanza- 
das 
Phase 2 
Adverse events 
Ankle-brachial index 
Transcutaneous oxygen pressure (TcO2)/Greater ulcer size 
Degree of rutherford-becker 
Perimeter calf muscle 
faster opacity in infra-popliteal vessels at 6 months com- 
pared with the basal situation of the patient 
NCT01484574 A clinical trial to study the efficacy and 
safety of different doses of bone marrow 
derived mesenchymal stem cells in patients 
with critical limb ischemia due to buergers 
disease 
Stempeutics Research Pvt Ltd 
Phase 2 
Relief of the rest pain 
Healing of ulcerations or reduction of ulcer area in the target 
limb|Relief of the rest pain 
Healing of ulcerations or reduction of ulcer area in the target 
limb|Pain free walking distance 
Major amputation free survival 
Ankle brachial pressure index (ABPI) - measured by Dop- 
pler 
Increase in transcutaneous partial oxygen pressure (TcPO2) 
Quality of life by King's College VascuQOL questionnaire 
Angiogenesis - collateral blood vessels by Magnetic reso- 
nance angiogram (MRA) 
The type of adverse events AE(s), number of AE(s) and 
proportion of patients with AE(s) 
NCT01257776 Human adipose derived mesenchymal stem 
cells for critical limb ischemia in diabetic 
patients 
Fundaciìn PÌ\1blica Andaluza 
Progreso y Salud 
Phase 1/Phase 2 
Angiographic assessment of neovasculogenesis (angiogene- 
sis plus arteriogenesis) 
Major adverse event (death, target limb amputation) 
Ankle brachial index/University of Texas Classification at 
target limb 
NCT00488020 Stem cells for treating critical ischemia Instituto de Molestias Cardio- 
vasculares 
Phase 1 
Suppress pain and heal ischemic ulcers/improve quality of 
life 
NCT01049919 Safety and efficacy study of autologous 
concentrated bone marrow aspirate (cBMA) 
for Critical Limb Ischemia (CLI) 
Biomet, Inc./Biomet Biol- 
ogics, LLC 
Time to treatment failure/Perfusion and quality of life meas- 
urements 
NCT01351610 Tolerability and Efficacy of Intravenous 
Infusion of Autologous MSC_Apceth for 
the Treatment of Critical Limb Ischemia 
Apceth GmbH & Co. KG 
Phase 1/Phase 
Collection of adverse events 
Safety laboratory values 
ECG findings 
Analysis of inflammation markers 
Comparison of course of haemodynamic and vascular 
processes 
NCT00922389 A clinical trial on diabetic foot using pe- 
ripheral blood derived stem cells for Treat- 
ing Critical Limb Ischemia 
Beike Biotech India Pvt.ltd 
Phase 1/Phase 2 
Adverse events and laboratory parameters 
Trans cutaneous partial pressure of Oxygen: TCpO2 
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NCT01216865 
 
Umbilical cord mesenchymal stem cells 
injection for diabetic foot 
Qingdao University 
 
Phase 1/Phase 2 
 
Angiographic evaluation of angiogenesis at ischemic 
limb and pain 
Ankle-brachial pressure index Wound 
healing (wound size, wound stage) 
Walking distance 
Rate and extent of amputations 
NCT01686139 Safety study of stem cells treatment in 
diabetic foot ulcers 
Sheba Medical Center 
Phase 1/Phase 2 
Frequency of adverse events/Healing of all wounds in the 
target limb 
NCT01824069 Treatment CLI nonrevascularizable lower 
limb with cell therapy 
Instituto de Investigaciìn 
Hospital Universitario La 
Paz/Hospital Universitario 
La Paz 
Phase 1/Phase 2 
Safety of inject mesenchymal stem cells in MMII 
Quality of life of patients after treatment 
NCT01916369 Safety trial of CTX cells in patients with 
lower limb ischaemia 
Reneuron Limited 
Phase 1 
Incidence of adverse events 
NCT00919516 Autologous bone marrow mononuclear cell 
implantation for moderate to severe periph- 
eral arterial disease 
The vascular and vein center, 
columbus, OH 
Major limb amputation 
Improved ABI measurements 
Relief of rest pain 
Ulceration healing 
NCT00411840 Novel therapy of PAD by combined trans- 
plantation of BMCs 
Heinrich-Heine University, 
Duesseldorf 
Phase 1 
ABI, walking distance, capillary-venous oxygen saturation, 
venous occlusion plethysmography 
NCT00113243 Safety study of using stem cells to stimulate 
development of new blood vessels in pe- 
ripheral vascular disease 
Murphy, Michael P., 
MD/Indiana University School 
of Medicine 
Phase 1 
Adverse events recorded in the 12 week study period 
 
Serious Adverse events recorded for one year 
Changes in limb perfusion after treatment with stem 
cells will be assessed with arteriography, blood 
pressure recordings, oxygen measurements, and 
wound healing 
NCT01558908 Phase I/II trial of endometrial regenerative 
cells (ERC) in patients with critical limb 
ischemia 
Medistem Inc. 
Phase 1/Phase 2 
Safety 
 
Efficacy 
NCT01903044 Safety and efficacy of autologous bone 
marrow stem cells for lower extremity 
ischemia treating 
Universidade Catìlica do 
Paranìá/Instituto de Mo- 
lÌ©stias Cardiovasculares Rio 
Preto, Brazil 
Phase 1/Phase 2 
Wound healing (wound size, wound stage) - monitoring the 
healing of trophic lesions 
Pain and analgesics use 
Quality of life outcome 
Improvement of the coronary and collateral circulation. 
Survival without amputation 
NCT00442143 Treatment of severe limb ischemia with 
autologous bonemarrow derived mononu- 
clear cells 
Odense University Hospital 
Phase 1 
Transcutaneous oxygen pressure. 1st toe blood pressure 
(strain gauge)/Ankle blood pressure. Wound healing. 
Pain amputation. Infection 
 
Clinical  trial  number  NCT00747708,   is  a  randomized trial investigating the co-administration  of bone marrow pro- genitor 
cells with Granulocyte colony-stimulating  factor (G- CSF) in patients with left ventricular dysfunction  secondary 
to ischemic heart disease. The study has three arms; Arm 1, patients will receive G-CSF or placebo peripheral injection. Arm 2, 
percutaneous intracoronary injection of G-CSF fol- lowed by BM progenitor cells or placebo. Arm 3, percutaneous intracoronary  
injection of G-CSF followed by intramyo- cardial injection of BM progenitor cells or placebo. G-CSF is widely used in bone 
marrow transplantation to induce hema- topoietic stem cell mobilization, more recently G-CSF was observed to influence stromal 
cell-derived  factor 1 (SDF-1) and its receptor CXCR4 levels, increasing homing of trans- planted cells and reducing apoptosis of 
   
cardiomyocytes  [73- 
76]. 
 
An interesting clinical trial is currently investigating the effectiveness  of  rapid  stem  cell  therapy  in  MI. NCT00765453  is a 
Phase 2 trial aiming to assess if myocardium can be recovered by combining stem cell therapy with primary angioplasty. 
BMMNC will be administered within 5 hours of a MI at the same time as primary angioplasty.  Primary outcome will be 
assessed by longitudinal change in LV ejection fraction over 1 year. 
Clinical  trial  NCT01569178   and  2006-000280-28   are both assessing safety of stem cells administration. 
Clinical trial 2006-000280-28, will deliver bone marrow mononuclear cells via intracoronary injection in patients with dilated  
cardiomyopathy  secondary  to  myocardial  ischemia. Its aim is to demonstrate that a single intracoronary  infusion of  autologous  
bone  marrow-derived   mononuclear  cells  is safe and reduces all-cause mortality in patients. 
 
Clinical trial 2006-000280-28, is a Phase I/II safety toler- ability test administering a dose escalation of adult haema- topoietic 
stem cells to patients with established myocardial ischemia. 
Clinical trial NCT01916369 sponsored by ReNeuron is currently recruiting in the UK focusing on PAD. It is a Phase I dose 
safety study of intramuscular  administration  of CTX0E03 which is a neural stem cell line. The primary objective   is   to   assess   
the   safety   of   increasing   doses   of CTX0E03  in addition  to tolerability  of intramuscular  injec- tion. This trial to be 
conducted  in patients with PAD is re- lated to the patent WO2010089605, which describes the in- vention of CTX0E03 for PAD 
treatment. 
 
Clinical trial NCT01558908  by Medistem Inc. are utiliz- ing  endometrial  regenerative  cells  in  patients  with  critical limb  
ischemia.  This  promising  use  of  endometrial-derived cells is being fully utilized in heart failure. Currently endo- metrial 
regenerative cells are in Phase II clinical trials for congestive heart failure [74]. Regenerative cells from the endometrium are 
reported to be superior to other sources of regenerative cells as they have greater expansion capability [74]. Bearing in mind that 
endogenous growth factors reside in the endometrium  and this  is an organ  with great  angio- genic  potential.  These  clinical  
trials  are  probably  utilizing patent US20130315875 [59] describing the use of novel angiogenic cells isolated from amnion, called 
“amnion derived adherent cells” (AMDACs) 
 
CONCLUSION 
 
Similar to industrial revolution which saw a steep rise in patent applications  the advent of potential far-reaching technologies 
brings forward today’s prospectors and pioneers driving   substantial   increase   in  patent  submission   laying claim to their 
invention. So, it is no surprise that the explosion in stem cell publications has led to a rapid and sustained growth in patent 
submissions in regenerative medicine. Applications  range  from  sourcing  new  stem  cell  populations from different tissue or 
providing selection criteria. These patents are currently being vigorously tested in clinical trials for safety  and efficacy,  in the 
hope that real breakthroughs can be made. Investigations are now focusing on how to im- prove patency of stem cells and 
include methods modifying the  microenvironment,   timing  of  stem  cell  treatment  and genetic makeup of the stem cells 
themselves. With the sheer number  of patents and scientists  focusing  on this field that even if a small proportion of these 
patents can be realized it is great hope this would lead to unlimited benefit for ischemic cardiovascular disease. 
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LIST OF ABBREVIATIONS 
 
MI = Myocardial infarct 
 
PAD = Peripheral artery disease HSCs =  Hematopoietic stem cells PTH =  
Parathyroid Hormone 
PTHrP = Parathyroid Hormone-Related  Peptide G-CSF  = Granulocyte Colony Stimulating Factor DPP 
IV = Dipeptidyl Peptidase IV 
HSCs = Hematopoietic Stem Cells 
 
IGF-1 = Insulin Growth Factor-1 
 
VEGF = Vascular Endothelial Growth Factor 
 
EPCs = Endothelial Progenitor Cells 
 
   
MSCs = Mesenchymal Stem Cells 
 
MAPCs  = Multipotent Adult Progenitor Cells MPCs = Mesenchymal Precursors Cells PTGIS = 
 Prostacyclin Synthase 
HMOX1  = Heme Oxygenase 
 
eNOS = Endothelial Nitric Oxide Synthase 
 
PAH = Pulmonary Arterial Hypertension 
 
PVD = Peripheral Vascular Disease 
 
CLI = Critical Limb Ischemia 
 
PDACs  = Placenta Derived Adherent Cells MACS  = Magnetic Activated Cell Sorting FACS = 
 Fluorescence Activated Cell Sorting CHD = Congenital Heart Disease 
AMDACs  = Amnion Derived Adherent Cells 
 
BH4 = Tetrahydrobiopterin 
 
G-CSF  = Granulocyte Colony-Stimulating  Factor 
 
PDACs  = Placenta Derived Adherent Cells 
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